Calidi Biotherapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
CLDI$0.68-6.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| (Unaudited) | ||||
| OPERATING EXPENSES | ||||
| Research and development | $(2,167) | $(3,177) | $(4,910) | $(5,799) |
| General and administrative | (3,605) | (3,360) | (7,614) | (6,152) |
| Total operating expense | (5,772) | (6,537) | (12,524) | (11,951) |
| Loss from operations | (5,772) | (6,537) | (12,524) | (11,951) |
| OTHER INCOME (EXPENSES), NET | ||||
| Interest expense | (108) | (98) | (206) | (165) |
| Interest expense – related party | (165) | (208) | (320) | (358) |
| Change in fair value of debt, other liabilities, and derivatives | 86 | (1,074) | (112) | (2,100) |
| Change in fair value of debt, other liabilities, and derivatives – related party | 9 | (2,773) | 8 | (3,260) |
| Series B preferred stock financing costs – related party | — | (2,680) | — | (2,680) |
| Grant income | 181 | 889 | 181 | 1,580 |
| Other income (expense), net | 10 | (16) | (7) | (21) |
| Total other income (expenses), net | 13 | (5,960) | (456) | (7,004) |
| LOSS BEFORE INCOME TAXES | (5,759) | (12,497) | (12,980) | (18,955) |
| Income tax provision | (8) | (4) | (12) | (8) |
| NET LOSS | $(5,767) | $(12,501) | $(12,992) | $(18,963) |
| Deemed dividend on warrants | (1,671) | — | (1,671) | — |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | $(7,438) | $(12,501) | $(14,663) | $(18,963) |
| Net loss per share; basic and diluted | $(1.40) | $(14.24) | $(3.30) | $(21.75) |
| Weighted average common shares outstanding; basic and diluted | 5,328 | 878 | 4,442 | 872 |
CALIDI BIOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| (Unaudited) | ||||
| NET LOSS | $(5,767) | $(12,501) | $(12,992) | $(18,963) |
| Other comprehensive income (expense), net of tax: | ||||
| Foreign currency translation adjustment | (38) | (5) | 20 | (3) |
| COMPREHENSIVE LOSS | $(5,805) | $(12,506) | $(12,972) | $(18,966) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.